In this article

GSK-GB

Follow your favorite stocks CREATE FREE ACCOUNT

GSK's CEO Emma Walmsley will step down in December and be replaced by insider Luke Miels, the British drugmaker said on Monday, tasking the new leader to deliver shareholder value and prepare for the next wave of R&D.

After nine years in the role, Walmsley, the most senior female CEO in the UK, will step down before her contract ends in September next year.

Since taking over in 2017, she has overseen the separation of consumer healthcare group Haleon and turned GSK's focus to cancer and infectious diseases as she drove efforts to counter a combination of patent expiries and declining revenue from its best-selling medicines by 2030.

However, she has struggled to win over investors due to concerns about GS

See Full Page